ERASCA INC
NASDAQ: ERAS (Erasca, Inc.)
Kemas kini terakhir: 19 jam lalu14.74
0.16 (1.10%)
| Penutupan Terdahulu | 14.58 |
| Jumlah Dagangan | 3,836,939 |
| Harga / Buku (P/B) | 13.48 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.570 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.72% |
| Nisbah Semasa (MRQ) | 12.35 |
| Aliran Tunai Operasi (OCF TTM) | -107.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -91.89 M |
| Pulangan Atas Aset (ROA TTM) | -22.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Erasca, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.69% |
| % Dimiliki oleh Institusi | 84.38% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |